Stockholm Stock Exchange | Mid Cap
Synact Pharma
+254.17%
Latest
-
3 months
ABG Sundal CollierKempen

Price Targets For Synact Pharma

AnalystPrice TargetDateUpside
ABG Sundal Collier170 SEKDec -21
+254.17%
Kempen125 SEKJun -21

About The Company

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.
Synact Pharma